Anti-Cancer Drugs最新文献

Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer. 使用 nivolumab 5 年后的超晚期重大反应：头颈癌进展后治疗的作用。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-06-28 DOI: 10.1097/CAD.0000000000001635

Santiago Cabezas-Camarero, María Nieves Cabrera-Martín, María Cruz Iglesias-Moreno, Pedro Pérez-Segura

{"title":"Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.","authors":"Santiago Cabezas-Camarero, María Nieves Cabrera-Martín, María Cruz Iglesias-Moreno, Pedro Pérez-Segura","doi":"10.1097/CAD.0000000000001635","DOIUrl":"10.1097/CAD.0000000000001635","url":null,"abstract":"Patients with recurrent/metastatic (R/M) platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) have fewer treatment options and harbor an especially poor prognosis. Maintaining treatment with anti-PD1 agents beyond response evaluation criteria in solid tumors-defined disease progression (TBP) has been shown to be efficacious in several solid tumors, including head and neck cancer. We present the case of a platinum-refractory locally recurrent, PD-L1-negative hypopharyngeal carcinoma, that received second-line nivolumab which was then maintained beyond progression under the following criteria: no Eastern Cooperative Oncology Group performance status deterioration, no rapidly progressive disease, no severe toxicity, and evidence of overall treatment benefit. The patient achieved a partial response 8 months after starting second-line nivolumab, with progressive disease at 26 months, then followed by the first TBP with nivolumab lasting for 15 months due to a new tumor progression. A second TBP with nivolumab lasting for 7 months, was followed by a third TBP with nivolumab for 12 months and achieving a major tumor response. Treatment is still ongoing 60 months after starting nivolumab, with excellent tolerance to therapy. Maintaining anti-PD1 agents beyond progression is an efficacious treatment option for patients with R/M SCCHN, that may achieve very durable disease control and even late major responses.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients? 口服纳米姜黄素制剂是预防癌症患者顺铂诱发肾毒性的安全有效措施吗？

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1097/CAD.0000000000001639

Sare Hosseini, Sara Rahsepar, Sara Naghipour, Sepideh Elyasi

{"title":"Is oral nano-curcumin formulation a safe and effective measure for preventing cisplatin-induced nephrotoxicity in cancer patients?","authors":"Sare Hosseini, Sara Rahsepar, Sara Naghipour, Sepideh Elyasi","doi":"10.1097/CAD.0000000000001639","DOIUrl":"10.1097/CAD.0000000000001639","url":null,"abstract":"Nephrotoxicity is one of the most important complications in cancer patients under treatment with cisplatin-containing regimens. Curcumin, as the most important active component of Curcuma longa, is an antioxidant and anti-inflammatory compound. In this clinical trial, we assessed the preventive effect of nano-curcumin oral formulation against cisplatin-induced nephrotoxicity in cancer patients. In this triple-blind clinical trial 30 cancer patients on cisplatin were randomly included in the treatment group, receiving nano-curcumin 40 mg capsules ( n = 15) or the placebo group ( n = 15) twice a day during four chemotherapy courses. Kidney function was measured at the beginning of the study and then at the end of each course of chemotherapy. There was no significant difference in acute kidney injury occurrence rate and creatinine and blood urine nitrogen serum levels between the treatment and placebo groups at the end of each chemotherapy course ( P value >0.05). Just at the end of the first course, the difference was close to significant ( P = 0.055). We also found no difference in mortality and recurrence rate in an average 30-month follow-up. Nano-curcumin in the prescribed dose and duration was not effective in preventing cisplatin-induced nephrotoxicity in cancer patients in comparison with the placebo. Further studies with larger sample size using different doses and duration of nano-curcumin are recommended.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial. 通过 IVOPAK II 试验中的跨学科合作，对右侧转移性结肠癌进行生物标志物分层一线治疗。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-08-07 DOI: 10.1097/CAD.0000000000001636

Francesco Vitali, Susanne Merkel, Christoph Schubart, Axel Schmid, Markus Eckstein, Robert Stöhr, Stephan Kersting, Arndt Hartmann, Robert Grützmann, Axel Wein

{"title":"Biomarker-stratified first-line treatment of right-sided metastatic colon cancer with interdisciplinary collaboration in the IVOPAK II trial.","authors":"Francesco Vitali, Susanne Merkel, Christoph Schubart, Axel Schmid, Markus Eckstein, Robert Stöhr, Stephan Kersting, Arndt Hartmann, Robert Grützmann, Axel Wein","doi":"10.1097/CAD.0000000000001636","DOIUrl":"10.1097/CAD.0000000000001636","url":null,"abstract":"Patients with right-sided metastatic colon carcinoma have a significantly worse prognosis than those with left-sided colorectal cancer (CRC), regardless of treatment. The aim of the prospective IVOPAK II study was to implement an interdisciplinary guideline-conform personalized CRC palliative therapy of metastatic colorectal carcinoma and to improve the overall survival (OS) by multidisciplinary approach via secondary metastatic resection. We present the efficacy data of first-line treatment and the benefit of interdisciplinary collaboration of right-sided metastatic colon carcinoma patients: n = 25. RAS mutation: n = 20 (80%): received systemic first-line treatment: FOLFIRI plus bevacizumab. All-RAS-wildtype: n = 5 (20%): received systemic first-line treatment: FOLFIRI plus cetuximab. Last date evaluation: 31 January 2024. Median age: 59.6 years (range 42-71), men/women: 14/11. Eastern Cooperative Oncology Group (ECOG) index: 0/1/2 : 11/10/4. Evaluable for response: n = 25. Complete response: n = 0, partial response: n = 14 (56%), stable disease: n = 8 (32%), progressive disease: n = 3 (12%), early tumor shrinkage: n = 13 (52%), estimates progression-free survival: 13 months (95% CI 8-17 months), estimated OS: 48 months (95% CI 25-71 months), median follow-up: 26 months (1-61 months), no evidence of disease: n = 4 (16%). A chemotherapy doublette regimen with FOLFIRI plus a biological as first-line treatment shows promising efficacy and secondary metastatic resection after interdisciplinary discussion was associated with a survival benefit in right-sided metastatic colon carcinoma.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dermatological toxicity associated with the use of gilteritinib in relapsed acute myeloid leukemia with FLT3 mutation: a case report. 在FLT3基因突变的复发急性髓性白血病患者中使用吉特替尼引起的皮肤毒性：病例报告。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-08 DOI: 10.1097/CAD.0000000000001634

Alicia Martín Roldán, Carolina Alarcón-Payer, María Del Mar Sánchez Suárez, Alberto Jiménez Morales

引用次数: 0

Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report. 一名低级别眼眶 B 细胞淋巴瘤患者的利妥昔单抗诱发白细胞破坏性血管炎：病例报告。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI: 10.1097/CAD.0000000000001638

Nesime İnci Güner, Ömer Dizdar, Alev Türker, Aygin Bayraktar-Ekincioglu

引用次数: 0

Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation. 通过诱导自噬和协调细胞周期与增殖，磺胺嘧啶靶向 xCT 可抑制三阴性乳腺癌的生长。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI: 10.1097/CAD.0000000000001630

Yaping Long, Zizheng Xu, Jing Yu, Xiao Hu, Yu Xie, Xianxian Duan, Ning Li, Yan Yan, Yue Wang, Junfang Qin

{"title":"Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation.","authors":"Yaping Long, Zizheng Xu, Jing Yu, Xiao Hu, Yu Xie, Xianxian Duan, Ning Li, Yan Yan, Yue Wang, Junfang Qin","doi":"10.1097/CAD.0000000000001630","DOIUrl":"10.1097/CAD.0000000000001630","url":null,"abstract":"There is a substantial unmet need for effective treatment strategies in triple-negative breast cancer (TNBC). Recently, renewed attention has been directed towards targeting glutamine (Gln) metabolism to enhance the efficacy of cancer treatment. Nonetheless, a comprehensive exploration into the mechanistic implications of targeting Gln metabolism in TNBC is lacking. In this study, our objective was to probe the sensitivity of TNBC to alterations in Gln metabolism, using representative TNBC cell lines: MDA-MB-231, MDA-MB-468, and 4T1. Through an integration of bioinformatics, in-vitro, and in-vivo investigations, we demonstrated that sulfasalazine (SAS), like erastin (a known xCT inhibitor), effectively suppressed the expression and transport function of xCT, resulting in a depletion of glutathione levels in MDA-MB-231 and MDA-MB-468 cells. Furthermore, both xCT knockdown and SAS treatment demonstrated the promotion of cellular autophagy. We unveiled a positive correlation between xCT and the autophagy-related molecule p62, their co-expression indicating poor survival outcomes in breast cancer patients. In addition, our research revealed the influence of SAS and xCT on the expression of proteins regulating cell cycle and proliferation. Treatment with SAS or xCT knockdown led to the inhibition of MYC, CDK1, and CD44 expression. Significantly, the combined administration of SAS and rapamycin exhibited a synergistic inhibitory effect on the growth of transplanted breast tumor in mouse models constructed from murine-derived 4T1 cells. Taken together, our findings suggested the potential and clinical relevance of the SAS and rapamycin combination in the treatment of TNBC.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regulation of cervical cancer via G15-mediated inhibition of G protein-coupled estrogen receptor. 通过 G15 介导的 G 蛋白偶联雌激素受体抑制宫颈癌的发生。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-17 DOI: 10.1097/CAD.0000000000001640

Ziyan Zhu, Xinyi Nie, Lexiu Deng, Jia Ding, Jiangping Chen, Jingyi Zhu, Xiaoxia Yin, Bowei Guo, Fan Zhang

{"title":"Regulation of cervical cancer via G15-mediated inhibition of G protein-coupled estrogen receptor.","authors":"Ziyan Zhu, Xinyi Nie, Lexiu Deng, Jia Ding, Jiangping Chen, Jingyi Zhu, Xiaoxia Yin, Bowei Guo, Fan Zhang","doi":"10.1097/CAD.0000000000001640","DOIUrl":"10.1097/CAD.0000000000001640","url":null,"abstract":"Cervical cancer is among the most common gynecological malignancies. G protein-coupled estrogen receptor (GPER) is involved in the development of various tumors; however, its role in cervical cancer remains unclear. We investigated whether G15, an inhibitor of GPER, can regulate its expression and affect cervical cancer progression. We examined the biological behaviors of G15-treated SiHa and HeLa cells using Cell Counting Kit-8, monoclonal proliferation, plate scratching, and Transwell invasion experiments. Western blotting was used to detect the expression of GPER, E-cadherin, N-cadherin, vimentin, Bcl-2, Bax, phosphatidylinositol-3-kinase (PI3K)/AKT, and programmed death ligand 1 (PD-L1). The expression of GPER, E-cadherin, vimentin, and PD-L1 in cervical cancer and adjacent tissues was detected using immunohistochemistry. The correlation between GPER expression and clinicopathological characteristics was analyzed. The expression of GPER in cervical cancer tissues was significantly higher than that in paracancerous tissues, and it was detected in the membrane and cytoplasm of SiHa and HeLa cells. The proliferation, migration, and invasion abilities of SiHa and HeLa cells were reduced after G15 treatment. The G15-treated groups exhibited higher expression of E-cadherin and Bax and lower expression of N-cadherin, vimentin, Bcl-2, GPER, p-PI3K, p-AKT, and PD-L1 than the control group. The expression of E-cadherin was lower and that of vimentin was higher in cancer tissues than in paracancerous tissues; PD-L1 was highly expressed in tumor and stromal cells in cancer tissues but not in paracancerous tissues. G15 functions by regulating the GPER/PI3K/AKT/PD-L1 signaling pathway and may serve as a new immunotherapy for treating patients with cervical cancer.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method. 利用高效液相色谱法，基于治疗药物监测对中国急性髓性白血病患者进行韦尼替克的个体化用药。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-08 DOI: 10.1097/CAD.0000000000001632

Yue Tang, Peng Rao, Shuojiao Li, Wenxian Yu, Ranran Wang, Jiatao Liu

{"title":"Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method.","authors":"Yue Tang, Peng Rao, Shuojiao Li, Wenxian Yu, Ranran Wang, Jiatao Liu","doi":"10.1097/CAD.0000000000001632","DOIUrl":"10.1097/CAD.0000000000001632","url":null,"abstract":"Objective: The aim of this study was to establish a simple and sensitive high-performance liquid chromatography method for therapeutic drug monitoring of venetoclax (VEN) and optimize regimens.Methods: The analysis required the extraction of a 50 μl plasma sample and the precipitation of proteins using acetonitrile extraction. The chromatographic method employed a mobile phase of acetonitrile: 0.5% KH 2 PO 4 (pH 3.5) (60/40, v/v) on a Diamond C 18 (4.6 mm × 250 mm, 5 μm) column at a flow rate of 1.0 ml/min. The quantitative method was validated based on standards described in 'Bioanalytical Method Validation: Guidance for Industry' published by the US Food and Drug Administration (FDA).Results: The calibration curve was linear ( R2 = 0.9998) over the range of 75-4800 ng/ml, with limits of quantification of 25 ng/ml. The coefficients of intraday and interday validation, specificity, recovery, and stability all met the criteria of FDA guidance. The method was successfully applied to analyze VEN concentrations in 30 cases of acute myeloid leukemia patients. The peak concentration ( Cmax ) was 1881.19 ± 756.61 ng/ml, while the trough concentration ( Cmin ) was 1212.69 ± 767.92 ng/ml in acute myeloid leukemia patients.Conclusion: Our study establishes a simple, precise, and sensitive high-performance liquid chromatography method for monitoring VEN and confirms its applicability for therapeutic drug monitoring of VEN in hematological cancers.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells. 多奈非尼可抑制 PARP1 的表达并诱导 DNA 损伤，与 PARP1 抑制剂联合使用可促进肝癌细胞凋亡。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-06-26 DOI: 10.1097/CAD.0000000000001631

Jiuliang Jiang, Pingping Yang, Xinyu Xu, Huixiong Yuan, Haitao Zhu

{"title":"Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells.","authors":"Jiuliang Jiang, Pingping Yang, Xinyu Xu, Huixiong Yuan, Haitao Zhu","doi":"10.1097/CAD.0000000000001631","DOIUrl":"10.1097/CAD.0000000000001631","url":null,"abstract":"Liver cancer is a prevalent malignant tumor globally. The newly approved first-line drug, donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant antitumor effects on liver cancer. This study aims to investigate the antitumor effects of donafenib on liver cancer and to explore its potential mechanisms. Donafenib significantly inhibited the viability of Huh-7 and HCCLM3 cells, inhibited malignant cell proliferation, and promoted cell apoptosis, as demonstrated by CCK-8, EdU, and Calcein/PI (propidium iodide) staining experiments. The results of DNA damage detection experiments and western blot analysis indicate that donafenib caused considerable DNA damage in liver cancer cells. The analysis of poly (ADP-ribose) polymerase 1 (PARP1) in liver cancer patients using online bioinformatics data websites such as TIMER2.0, GEPIA, UALCAN, cBioPortal, Kaplan-Meier Plotter, and HPA revealed a high expression of PARP1, which is associated with poor prognosis. Molecular docking and western blot analysis demonstrated that donafenib can directly target and downregulate the protein expression of PARP1, a DNA damage repair protein, thereby promoting DNA damage in liver cancer cells. Western blot and immunofluorescence detection showed that the group treated with donafenib combined with PARP1 inhibitor had significantly higher expression of γ-H2AX and 8-OHdG compared to the groups treated with donafenib or PARP1 inhibitors alone, the combined treatment suppresses the expression of the antiapoptotic protein Bcl2 and enhances the protein expression level of the proapoptotic protein Bcl-2-associated X protein (BAX). These data suggest that the combination of donafenib and a PARP1 inhibitor results in more significant DNA damage in cells and promotes cell apoptosis. Thus, the combination of donafenib and PARP1 inhibitors has the potential to be a treatment option for liver cancer.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer. 一名肺癌患者在接受乐拉替尼治疗期间，其左侧脑膜受累症状完全和持久消退。

IF 1.8 4区医学

Anti-Cancer Drugs Pub Date : 2024-10-01 Epub Date: 2024-07-09 DOI: 10.1097/CAD.0000000000001637

Giorgia Guaitoli, Enrica Martinelli, Lucia Trudu, Isacco Desideri, Pietro Mortini, Stefano Greco, Alessio Bruni, Daniela Greto, Guido Pecchioli, Chiara Chiavelli, Massimo Dominici, Federica Bertolini

{"title":"Complete and durable regression of leptomeningeal involvement during lorlatinib treatment in a patient with lung cancer.","authors":"Giorgia Guaitoli, Enrica Martinelli, Lucia Trudu, Isacco Desideri, Pietro Mortini, Stefano Greco, Alessio Bruni, Daniela Greto, Guido Pecchioli, Chiara Chiavelli, Massimo Dominici, Federica Bertolini","doi":"10.1097/CAD.0000000000001637","DOIUrl":"10.1097/CAD.0000000000001637","url":null,"abstract":"Metastatic spread to the central nervous system (CNS) is frequent in anaplastic lymphoma kinase ( ALK )-rearranged non-small cell lung cancer (NSCLC) and has an important impact on patient prognosis and quality of life. Leptomeningeal involvement may occur in up to 10% of cases of ALK-positive NSCLC. Lorlatinib is a third-generation ALK inhibitor that has excellent CNS penetrability and demonstrated its efficacy both in pretreated and treatment-naive patients. Herein, we present the case of a 34-year-old patient diagnosed with stage IV ALK-rearranged NSCLC who received two lines of ALK inhibitors (crizotinib followed by alectinib) and several courses of brain stereotactic ablative radiotherapy until leptomeningeal involvement was detected. Third-line lorlatinib was then administered, and 2 months later encephalic MRI documented complete regression of the leptomeningeal involvement that is still maintained after 36 months while treatment with lorlatinib is still ongoing with good tolerability. To the best of our knowledge, this is the longer intracranial response reported in the literature, underlining the importance of the most appropriate choice of systemic treatments and their integration with loco-regional approaches to improve outcomes.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0